Comparative Pharmacology
Head-to-head clinical analysis: GEOPEN versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEOPEN versus PENICILLIN 2.
GEOPEN vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has activity against Gram-negative and some Gram-positive bacteria.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
2 g intravenously every 6 hours for susceptible infections.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
Terminal half-life 4-6 hours in normal renal function; prolonged to 10-20 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 30-50 hours in severe impairment (CrCl <10 mL/min).
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <2%.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic